drugset / Trial / NCT06422156
SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer
Phase 2
Unknown
73 enrolled
Peking University Third Hospital
Biotech Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, multicenter, single arm clinical study. The main purpose of the study is to evaluate the clinical efficacy and safety of SBRT combined with Nimotuzumab and mono-chemotherapy in the treatment of locally advanced pancreatic cancer (LAPC).
Timeline
- Start
- 2024-06-01
- Primary completion
- 2026-06-01
- Completion
- 2026-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Nimotuzumab | Monoclonal antibody | 400 mg | Intravenous |
| Subject | Nimotuzumab | Monoclonal antibody | 600 mg | Intravenous |
| Subject | S-1 | Small molecule | — | — |